title: Defining the initial doses of sirolimus and tacrolimus in the period immediately after renal transplantation.
authors.affiliation: Laboratory of Pharmacology, CBD, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
authors.forename: O
authors.initials: O
authors.lastname: Jiménez
authors.forename: J M
authors.initials: JM
authors.lastname: Campistol
authors.forename: E
authors.initials: E
authors.lastname: Vidal
authors.forename: A
authors.initials: A
authors.lastname: Faura
authors.forename: F
authors.initials: F
authors.lastname: Oppenheimer
authors.forename: J
authors.initials: J
authors.lastname: Corbella
authors.forename: M
authors.initials: M
authors.lastname: Brunet
mesh_terms: D000328:Adult; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015996:Survival Rate; D016559:Tacrolimus / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D003404:Creatinine; D020123:Sirolimus; D016559:Tacrolimus